Drug Trial Radar · NCT05091242
The PREVENT AGITATION Trial II - Children ≤1 Year
Last checked: Nov 20, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
336
Planned (sponsor's estimate)
Start
Oct 25, 2021
Primary completion
Jan 31, 2028
Study completion Jan 31, 2028
Sponsor
- Lead sponsor
- Copenhagen University Hospital, RigshospitaletAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 3 months, up to 12 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Emergence agitation is a clinical condition in which the child experiences a variety of behavioural disturbances including crying, thrashing, and disorientation during early awakening from anaesthesia. Emergence agitation is a common challenge in children with a reported incidence of approximately 25% ranging from 10 to 80 %. Clonidine is often used off-label in paediatric anaesthesia e.g. sedation in the intensive care unit, prevention of withdrawal symptoms after long-term sedation, as premedication before induction of anaesthesia or as treatment/prevention of emergence agitation. The study is designed as a randomised, placebo-controlled clinical trial evaluating efficacy and safety of a single dose of intraoperative clonidine in children 3-12 months, including pharmacokinetics.
Conditions
- Emergence Delirium
Interventions
ClonidineDrug
Clonidine injection 3 mcg/kg once
Sodium chlorideDrug
Sodium chloride 0.9 % injection 0.2 mL/kg once
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of emergence agitation during stay in postanaesthetic care unit (PACU)Time frame: From admission to PACU to discharge from PACU, up to app. 4 hours. Emergence agitation is considered present ("Yes"), if Watcha score>2 at ANY time point within the given time frame.
- Compartmental clearance for pharmacokinetic profiling.Time frame: Samples will be collected at baseline and at 5, 15, 30, and 60 minutes post dosage and just prior prior to removal of iv-access ie., at latest 120-240 min post dosage.
- Volume of distribution for pharmacokinetic profiling.Time frame: Samples will be collected at baseline and at 5, 15, 30, and 60 minutes post dosage and just prior prior to removal of iv-access ie., at latest 120-240 min post dosage.
- T1/2 for pharmacokinetic profiling.Time frame: Samples will be collected at baseline and at 5, 15, 30, and 60 minutes post dosage and just prior prior to removal of iv-access ie., at latest 120-240 min post dosage.
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Perth Children's Hospital, Department of Anaesthesia and Pain Medicine
Perth, Nedlands, Australia · Recruiting
Copenhagen University Hospital, Rigshospitalet
Copenhagen, Denmark · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.